Astrazeneca (AZN) Depreciation & Amortization (CF) (2009 - 2026)

Astrazeneca has reported Depreciation & Amortization (CF) for 18 years, with the latest figure at $1.9 billion in Q2 2026.

• On a quarterly basis, Depreciation & Amortization (CF) rose 38.88% year-over-year to $1.9 billion in Q2 2026; TTM through Jun 2026 was $6.4 billion, a 6.91% decrease from a year earlier, with the FY2025 full-year figure at $5.7 billion, down 14.28% from the prior year.
• Depreciation & Amortization (CF) was $1.9 billion for Q2 2026 at Astrazeneca, up from $1.4 billion in the prior quarter.
• The five-year high for Depreciation & Amortization (CF) was $4.1 billion in Q4 2023, with the low at $1.3 billion in Q1 2024.
• Average Depreciation & Amortization (CF) over 5 years is $1.8 billion, with a median of $1.4 billion recorded in 2023.
• The sharpest annual moves came in 2022 and 2024: Depreciation & Amortization (CF) soared 82.48% in 2022, then tumbled 42.44% in 2024.
• Over 5 years, Depreciation & Amortization (CF) stood at $4.0 billion in 2022, then climbed by 1.5% to $4.1 billion in 2023, then plunged by 42.44% to $2.3 billion in 2024, then tumbled by 35.34% to $1.5 billion in 2025, then grew by 27.66% to $1.9 billion in 2026.
• The last three Depreciation & Amortization (CF) figures came in at $1.9 billion (Q2 2026), $1.4 billion (Q1 2026), and $1.5 billion (Q4 2025), per Business Quant data.